Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Agenus announced the peer-reviewed publication of mature Phase 1b data in Clinical Cancer Research for botensilimab plus balstilimab in refractory MSS metastatic colorectal cancer. The treatment demonstrated a median overall survival of 21.2 months and a 33% three-year survival rate in 123 heavily pre-treated patients, significantly exceeding the historical standard of care. Biomarker analyses confirmed responses in immunologically "cold" tumors with low mutational burden and no PD-L1 expression, validating the Fc-enhanced mechanism of action.
Key figures
- Dcr
- 69%
- Orr
- 21%
- Patients
- 123
- Median os
- 21.2 months
- Subgroup orr
- 22%
- Subgroup median os
- 16.2 months
- Three year os rate
- 33%
- Prior lines therapy median
- 3
- Subgroup three year os rate
- 30%
- Disease control rate subgroup
- 70%
- Clinical benefit rate subgroup
- 27%
- Median duration of response subgroup
- 16.6 months
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.